MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial 12S rRNA region, one of a small family of mitochondrial-derived peptides that cells appear to produce under metabolic stress. It has moved from obscure cell biology to a prescription compounding formulary faster than the human data has moved at all, which makes it a useful case study in how far ahead of the evidence this category runs.

What the pain research found

The broadest body of work is in animal pain models, summarized in a mini review published in Frontiers in Pain Research and written up by Scienmag. In a spared nerve injury model, MOTS-c levels were reported as significantly decreased in plasma and spinal dorsal horn, and intrathecal MOTS-c produced dose-dependent antinociception linked to inhibition of spinal microglial activation.

Later work in streptozotocin-induced diabetic mice reported improved mechanical allodynia and thermal hyperalgesia after intrathecal, intraperitoneal or intraplantar delivery, with increased AMPKalpha1/2 phosphorylation and PGC-1alpha expression in the lumbar spinal cord. The same review notes effects reported in cancer-induced bone pain and in the formalin test of acute inflammatory pain. All of it is animal work. The authors state plainly that no mitochondrial-derived peptide has been clinically evaluated with pain as a primary endpoint.

The one human data point is indirect: CB4211, a MOTS-c analog, completed a Phase 1a/1b trial in nonalcoholic steatohepatitis and obesity under NCT03998514. It was well tolerated, and after four weeks liver enzymes and blood glucose were significantly reduced, with measurable reductions in liver fat. That trial was not designed for pain.

Injectable only, under a draft policy

MOTS-c is one of six peptides covered by the HHS enforcement discretion policy on 503A compounding, announced in the Federal Register on October 30, 2026 under docket HHS-OASH-2026-0496. Unlike BPC-157 and KPV, MOTS-c is recognized only for injectable forms, and the policy is a draft that does not constitute FDA approval of any peptide.

What the FDA reviewers said

The gap between that policy and the evidence is the story, and it was reported in detail by Celine Gounder, who notes that FDA drug reviewers recommended against listing all six peptides. HHS told her the policy "does not grant FDA approval or establish clinical safety and effectiveness," and its main added quality check is a certificate of analysis for the raw ingredient, with no test of the finished vial.

Already on a formulary

Commercial uptake did not wait. Superpower has launched a clinician-prescribed peptide program with BPC-157, TB-500 and MOTS-C in its initial lineup, taking pre-orders with shipping expected at the end of November 2026. The company's own disclosure states the peptides are compounded medications not approved by the FDA and that evidence on their safety and effectiveness in humans is limited.

What Isn't Established

There is no published human trial of MOTS-c itself with a pain endpoint, and the analgesic literature is entirely preclinical. The Phase 1 data belongs to an analog, in a metabolic indication, over four weeks.

The review authors also flag two unresolved questions: whether declining endogenous peptide levels drive pain or merely accompany it, and whether any analgesic effect is direct restoration of mitochondrial function or an indirect consequence of anti-inflammatory and anti-apoptotic pathways. Long-term safety in humans has not been characterized at all.

Where the evidence stands

MOTS-c has a coherent proposed mechanism, a reasonably broad animal literature across several distinct pain types, and one tolerability signal from an analog in a different indication. What it does not have is a single human efficacy trial, which is an odd thing to say about a compound now available through licensed pharmacies on a patient-specific prescription.